INTERCEPT PHARMACEUTICALS, INC.·4

Jan 27, 7:06 PM ET

Kim Richard J 4

4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 27, 2020

Insider Transaction Report

Form 4
Period: 2020-01-23
Kim Richard J
SVP, Commercial US
Transactions
  • Award

    Common Stock

    2020-01-23+5,40021,498 total
  • Award

    Option to Purchase Common Stock

    2020-01-23+8,8008,800 total
    Exercise: $99.66Exp: 2030-01-23Common Stock (8,800 underlying)
Footnotes (2)
  • [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
  • [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.

Documents

1 file
  • 4
    tm205922d8_4.xmlPrimary

    OWNERSHIP DOCUMENT